GLYC insider filings

GLYCOMIMETICS INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-08-09. Screen GLYC transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for GLYC between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — GLYCOMIMETICS INC

FiledFormInsiderReported transactionsSource
2024-08-094Invus Public Equities, L.P. — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Siren, L.L.C. — 10% owner
Invus Global Management, LLC — 10% owner
DEBBANE RAYMOND — 10% owner
Sale (S): 61,488 @ $0.18 · Sale (S): 260,873 @ $0.19EDGAR
2024-08-074Invus Public Equities, L.P. — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Siren, L.L.C. — 10% owner
Invus Global Management, LLC — 10% owner
DEBBANE RAYMOND — 10% owner
Sale (S): 164,523 @ $0.19 · Sale (S): 55,732 @ $0.18EDGAR
2024-08-054Invus Public Equities, L.P. — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Siren, L.L.C. — 10% owner
Invus Global Management, LLC — 10% owner
DEBBANE RAYMOND — 10% owner
Sale (S): 63,564 @ $0.22 · Sale (S): 286,200 @ $0.20EDGAR
2024-07-304Invus Public Equities, L.P. — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Siren, L.L.C. — 10% owner
Invus Global Management, LLC — 10% owner
DEBBANE RAYMOND — 10% owner
Sale (S): 258,335 @ $0.24 · Sale (S): 363,949 @ $0.24 · Sale (S): 756,835 @ $0.22EDGAR
2024-06-244Rock Edwin — Chief Medical OfficerPurchase (P): 190,000 @ $0.25 · Purchase (P): 115,000 @ $0.27EDGAR
2024-06-204Hahn Brian M. — SVP Finance, CFOPurchase (P): 17,500 @ $0.25EDGAR
2024-05-014Koenig Scott — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-05-014Goldberg Mark Alan — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-05-014PEARSON TIMOTHY R — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-05-014King Rachel K. — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-05-014Andrews Patricia S — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-05-014Jackson Scott Thomas — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-05-014JUNIUS DANIEL M — DirectorGrant/award (A): 40,000 (derivative) @ $0EDGAR
2024-04-024Goldberg Mark Alan — DirectorGrant/award (A): 4,584 @ $3EDGAR
2024-04-024King Rachel K. — DirectorGrant/award (A): 3,334 @ $3EDGAR
2024-04-024JUNIUS DANIEL M — DirectorGrant/award (A): 5,209 @ $3EDGAR
2024-01-174Johnson Bruce S — SVP & Chief Commercial OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-01-174Semerjian Harout — Chief Executive Officer, DirectorGrant/award (A): 695,000 (derivative) @ $0EDGAR
2024-01-174Rock Edwin — Chief Medical OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-01-174Rath Chinmaya — SVP and Chief Business OfficerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-01-174Hahn Brian M. — SVP Finance, CFOGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-01-024Andrews Patricia S — DirectorGrant/award (A): 5,191 @ $2.36EDGAR
2024-01-024King Rachel K. — DirectorGrant/award (A): 4,238 @ $2.36EDGAR
2024-01-024Goldberg Mark Alan — DirectorGrant/award (A): 5,827 @ $2.36EDGAR
2023-10-034Goldberg Mark Alan — DirectorGrant/award (A): 9,167 @ $1.50EDGAR
2023-10-034Andrews Patricia S — DirectorGrant/award (A): 8,167 @ $1.50EDGAR
2023-10-034King Rachel K. — DirectorGrant/award (A): 6,667 @ $1.50EDGAR
2023-09-254Rock Edwin — Chief Medical OfficerPurchase (P): 35,000 @ $1.38 · Purchase (P): 30,403 @ $1.38EDGAR
2023-06-024Koenig Scott — DirectorOption exercise (M): 21,000 @ $0.60 · Option exercise (M): 21,000 (derivative) @ $0EDGAR
2023-05-224King Rachel K. — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-224Koenig Scott — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-224Goldberg Mark Alan — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-224PEARSON TIMOTHY R — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-224Andrews Patricia S — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-224Jackson Scott Thomas — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-224JUNIUS DANIEL M — DirectorGrant/award (A): 35,000 (derivative) @ $0EDGAR
2023-05-184Hahn Brian M. — SVP Finance, CFOSale (S): 3,700 @ $1.95EDGAR
2023-05-114JUNIUS DANIEL M — DirectorPurchase (P): 30,000 @ $1.56EDGAR
2023-05-094Johnson Bruce S — SVP & Chief Commercial OfficerPurchase (P): 13,500 @ $1.57EDGAR
2023-02-284Invus Public Equities, L.P. — 10% owner
Artal International S.C.A. — 10% owner
Artal International Management S.A. — 10% owner
Artal Group S.A. — 10% owner
Westend S.A. — 10% owner
Wittouck Amaury — 10% owner
Stichting Administratiekantoor Westend — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Purchase (P): 100,000 @ $1.70EDGAR
2023-02-234Invus Public Equities, L.P. — 10% owner
Artal International S.C.A. — 10% owner
Artal International Management S.A. — 10% owner
Artal Group S.A. — 10% owner
Westend S.A. — 10% owner
Wittouck Amaury — 10% owner
Stichting Administratiekantoor Westend — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Purchase (P): 50,000 @ $1.85 · Purchase (P): 150,000 @ $1.79 · Purchase (P): 200,000 @ $1.75EDGAR
2023-02-174Invus Public Equities, L.P. — 10% owner
Artal International S.C.A. — 10% owner
Artal International Management S.A. — 10% owner
Artal Group S.A. — 10% owner
Westend S.A. — 10% owner
Wittouck Amaury — 10% owner
Stichting Administratiekantoor Westend — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Purchase (P): 1,000,000 @ $2.16 · Purchase (P): 315,266 @ $1.68 · Purchase (P): 200,000 @ $1.71EDGAR
2023-02-134Invus Public Equities, L.P. — 10% owner
Artal International S.C.A. — 10% owner
Artal International Management S.A. — 10% owner
Artal Group S.A. — 10% owner
Westend S.A. — 10% owner
Wittouck Amaury — 10% owner
Stichting Administratiekantoor Westend — 10% owner
Invus Public Equities Advisors, LLC — 10% owner
Purchase (P): 11,451 @ $3.24EDGAR
2023-01-304Koenig Scott — DirectorOption exercise (M): 10,500 @ $2.55 · Option exercise (M): 10,500 (derivative) @ $0EDGAR
2023-01-274SANDELL SCOTT D — 10% ownerSale (S): 358,371 @ $3.26 · Sale (S): 293,645 @ $3.26 · Sale (S): 1,648,908 @ $3.12 · Sale (S): 1,351,092 @ $3.12EDGAR
2023-01-204Hahn Brian M. — SVP Finance, CFOGrant/award (A): 246,300 (derivative) @ $0EDGAR
2023-01-204Semerjian Harout — Chief Executive Officer, DirectorGrant/award (A): 651,200 (derivative) @ $0EDGAR
2023-01-204Rock Edwin — Chief Medical OfficerGrant/award (A): 244,800 (derivative) @ $0EDGAR
2023-01-064SANDELL SCOTT D — 10% ownerSale (S): 39,223 @ $2.76 · Sale (S): 32,139 @ $2.76EDGAR
2023-01-044SANDELL SCOTT D — 10% ownerSale (S): 66,690 @ $3.02 · Sale (S): 54,645 @ $3.02 · Sale (S): 96,084 @ $2.99 · Sale (S): 78,730 @ $2.99 · Sale (S): 56,054 @ $2.91 · Sale (S): 45,930 @ $2.91EDGAR

Recent 8-K events — GLYCOMIMETICS INC

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-158-K8.01 — Other EventsEDGAR
2026-07-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-158-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-148-K2.02 — Results of Operations and Financial ConditionEDGAR
2026-06-038-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-04-298-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-048-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-068-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GLYC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs